The Uromigos

Episode 79: Adjuvant nivolumab in operable urothelial cancer 13.02.2021 24:36 ↓

Matt Galski discusses this potentially practice-changing study. 

Episode 78: Enfortumab Vedotin Special: EV301 randomised trial and EV201 in urothelial cancer 12.02.2021 22:39 ↓

Arjun Balar discusses these studies and the impact they will have. 

Episode 77: The Uromigos Paper of the Month - Nadofaragene for BCG unresponsive NMIBC 06.02.2021 17:21 ↓

Stephen Boorjian outlines his recent Lancet oncology paper. Tom and Brian struggle to keep up. 

Episode 76: Tom Hutson discusses lenvatinib and everolimus 22.01.2021 23:51 ↓

Discussion on lenvatinib and everolimus prior to the CLEAR trial presentation. 

Episode 75: The Uromigos meet APCCC - bone health and bone disease in prostate cancer with Bertrand Tombal 14.01.2021 25:47 ↓

Silke, Chris and Bertrand discuss bone protective therapy and bone targeted therapy. 

Episode 74: The Uromigos meet APCCC Round 2: First line treatment - low vs high volume; chemo vs abi/enza 11.01.2021 32:05 ↓

Nick James and Chris Sweeney debate this issue. Tom and Silke try to keep things on track. 

Episode 73: The Uromigos meet APCCC in a discussion on oligometastatic prostate cancer @APCCC_Lugano 08.01.2021 25:11 ↓

Piet Ost, Chris Sweeney and Silke Gillessen discuss controversies around the management of oligometastatic prostate cancer. 

Episode 72: Uromigos Christmas Special - Renal cancer year in review 21.12.2020 24:25 ↓

Laurence Albiges discusses renal cancer highlights from the year. 

Episode 71: Bladder Cancer Uromigos Christmas Special with Matt Galsky 18.12.2020 24:57 ↓

Matt discusses the year in review, including first line and adjuvant immune therapy studies, ADCs and FGFR targeting are also discussed. 

Episode 70: The Uromigos Prostate Cancer Christmas Special with Chuck Ryan 11.12.2020 25:56 ↓

A review of the year in prostate cancer with Chuck Ryan. 

Episode 69: Testis Cancer Christmas Special: 2020 year in review 09.12.2020 25:16 ↓

Christian Kollmannsberger gets into the Christmas spirit by discussing highlights of 2020. 

Episode 68: Uromigos Paper of the Month - a molecular classification of renal cancer in Cancer Cell 08.12.2020 26:24 ↓

Kim Rathmell discusses this paper, which divides clear cell renal cancer into seven relevant subgroups. Brian askes an interesting question at one point. 

Episode 67: The Third Uromigos Debate - PD1/VEGF vs PD1/CTLA4 for front line renal cancer 17.11.2020 28:48 ↓

David McDermott and Brian Rini debate treatment options in front line renal cancer. It's hard to identify any winners from this podcast.

Episode 66: Uromigos Paper of the Month - Two papers in Nature Medicine on neoadjuvant immune combinations in bladder cancer 09.11.2020 30:49 ↓

Pam Sharma and Michiel Van Der Heijden discuss neoadjuvant PD(L)1 + CTLA4 inhibition in urothelial cancer. 

Episode 65: Review of the International Kidney Cancer Symposium 02.11.2020 22:31 ↓

Gretchen Vaughan, Kidney Cancer Association CEO, discusses the upcoming International Kidney Cancer Symposium meeting and KCA's grant program. Tom and Brian review some of the top abstracts. 

Episode 64: The Second Uromigos debate with Nobel Laureate Bill Kaelin on new biomarker vs new drugs in RCC 28.10.2020 28:57 ↓

'New Drugs vs New Biomarkers' Bill Kaelin (Nobel Laureate) vs Tom Powles (keen cyclist), extend their discussion from KCRS20 in the 2nd Uromigos Debate. 

Episode 63: The First Uromigos Debate: front line immune therapy vs maintenance avelumab in bladder cancer 09.10.2020 21:19 ↓

Dr. Peter O'Donnell and Prof. Tom Powles debate front line treatment options in urothelial cancer. 

Episode 62: James Eastham's Uromigos Paper of the Month - Prostatectomy +/- Neoadjuvant Chemo 06.10.2020 27:44 ↓

A large randomised investigator-initiated Alliance study gives insight in to perioperative treatments for high risk prostate cancer. 

Episode 61: Nick James discusses the latest update of the STAMPEDE study 21.09.2020 17:16 ↓

Nick gives us a quick summary of the STAMPEDE study and gives an overview of the latest data. 

Episode 60: Cora Sternberg discusses AMG 160 - a bispecific antibody in prostate cancer 21.09.2020 14:58 ↓

AMG 160; a half-life extended (HLE) bispecific T-cell engager (BITE®) antibody construct is discussed as is the future of immune therapy in CRPC. 

Episode 59: Ipatercertib in biomarker positive castrate resistant prostate cancer 20.09.2020 25:33 ↓

Chris Sweeney (last author) discusses the ATK inhibitor Ipatercertib in pTEN altered CRPC. A positive R3 trial in the ESMO plenary session. 

Episode 58: Brilliant ESMO discussant Richard Cathomas talks to Brian and Tom about the meaning of DANUBE and KN362 19.09.2020 26:44 ↓

The group go into the detail of chemo immune combinations and what to do next. 

Episode 57: Toni Choueiri - cabo & nivo vs sunitinib in metastatic clear cell renal cancer 19.09.2020 26:12 ↓

The group attempts to put the data into context with the other available combinations.

Episode 56: Matt Galsky and Tom Powles discuss ESMO 2020 immune therapy data in bladder cancer 19.09.2020 27:40 ↓

The group try to get to the bottom of whether these data has made any difference in treatment and future plans. 

Episode 55: The Uromigos Paper of the Month - Cabozantinib in Bladder Cancer by Dr. Andrea Apolo 31.08.2020 23:26 ↓

Andrea talks about her phase 2 trial which shows activity for Cabozantinib in urothelial cancer.